$0.93 -$0.06 (-6.2%)

04:00 PM EST on 11/11/19

Infinity Pharmaceuticals, Inc. (NASDAQ:INFI)

CAPS Rating: 2 out of 5

The Company's mission is to discover, develop, and deliver to patients medicines for the treatment of cancer and related conditions.

Current Price $0.93 Mkt Cap $56.5M
Open $0.98 P/E Ratio 0.00
Prev. Close $0.99 Div. (Yield) $0.00 (0.0%)
Daily Range $0.88 - $1.00 Volume 340,586
52-Wk Range $0.82 - $1.95 Avg. Daily Vol. 125,705

Caps

This ticker is not currently Ratable.

Add Stock to CAPS Watchlist

All Players

96 Outperform
35 Underperform
 

All-Star Players

22 Outperform
15 Underperform
 

Wall Street

5 Outperform
2 Underperform
 

Top NASDAQ:INFI Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

phatchips767 (< 20)
Submitted April 14, 2012

80% increase since feb..

TrackUltraLong (< 20)
Submitted November 04, 2011

http://www.fool.com/investing/general/2011/07/15/3-stocks-near-52-week-highs-worth-selling.aspx

NASDAQ:INFI VS S&P 500 (SPY)

Fools bullish on NASDAQ:INFI are also bullish on:

Fools bearish on NASDAQ:INFI are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about INFI.

Recs

0
Member Avatar Bigsef77 (67.43) Submitted: 10/2/2018 2:00:53 PM : Outperform Start Price: $1.99 NASDAQ:INFI Score: -64.22

Infinity Pharmaceuticals Earns $22 Million Payment From Verastem Oncology For FDA Approval Of COPIKTRA™ (duvelisib) And Updates 2018 Financial Guidance
PR Newswire PR Newswire•October 1, 2018
CAMBRIDGE, Mass., Oct. 1, 2018 /PRNewswire/ -- Infinity Pharmaceuticals, Inc. (INFI) announced today that it earned a $22 million payment from Verastem Oncology under the license agreement between the Company and Verastem for COPIKTRA (duvelisib). The payment was earned upon the approval by the U.S. Food and Drug Administration (FDA) on September 24, 2018 of duvelisib for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) after at least two prior therapies, as well as accelerated approval for the treatment of adult patients with relapsed or refractory follicular lymphoma after at least two prior systemic therapies.

"We are really pleased that duvelisib is now available for patients with CLL/SLL and follicular lymphoma and are proud of the role Infinity played in its development," said Adelene Perkins, Chief Executive Officer and Chair of Infinity. "This $22 million FDA approval payment from Verastem supports Infinity's continued expansion of the development of IPI-549, our first-in-class, oral, immuno-oncology development candidate that selectively inhibits phosphoinositide-3-kinase-gamma (PI3K-gamma), including in doublet and triplet combination trials to identify the best combination regimens to treat patients with specific types of cancer."

In 2016, Infinity entered into a license agreement granting Verastem an exclusive worldwide license for the research, development, commercialization, and manufacture of duvelisib and products containing duvelisib in oncology. Pursuant to the terms of the license agreement, Verastem has notified Infinity of its election to make the $22 million payment in cash, which Infinity expects to receive later this year. Infinity also is eligible for royalties on worldwide net sales of duvelisib ranging from the mid-to-high single digits, shared equally with Takeda.

Recs

0
Member Avatar oscillation (69.38) Submitted: 6/14/2016 9:48:43 AM : Outperform Start Price: $1.51 NASDAQ:INFI Score: -86.54

nev

Recs

0
Member Avatar Marmadukemark (53.67) Submitted: 3/21/2015 5:44:18 PM : Outperform Start Price: $1.27 NASDAQ:INFI Score: -40.04

Oversold.

Leaderboard

Find the members with the highest scoring picks in INFI.

Score Leader

Zippidy3

Zippidy3 (30.64) Score: +307.38

The Score Leader is the player with the highest score across all their picks in INFI.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
Zippidy3 30.64 7/28/2009 Underperform 5Y $8.48 -89.04% +218.34% +307.38 0 Comment
KeepYourCoolFool 98.80 7/29/2009 Underperform 5Y $8.69 -89.31% +217.56% +306.87 0 Comment
whoitis 67.14 7/28/2009 Underperform NS $8.06 -88.47% +217.23% +305.70 0 Comment
SpencerHar < 20 8/3/2009 Underperform 3Y $8.07 -88.49% +210.51% +299.00 0 Comment
WallStreetRafael < 20 9/1/2010 Underperform 5Y $4.98 -81.35% +184.85% +266.20 0 Comment
longtermgrowth09 < 20 12/17/2009 Underperform 5Y $5.63 -83.50% +178.50% +261.99 0 Comment
mdicksonjr 98.94 5/21/2012 Underperform 5Y $12.49 -92.56% +136.90% +229.46 0 Comment
vjport < 20 5/23/2012 Underperform 1Y $12.27 -92.43% +134.93% +227.36 0 Comment
storkk < 20 6/12/2012 Underperform 5Y $12.47 -92.55% +133.97% +226.52 0 Comment
IBDContrarian 77.10 6/27/2012 Underperform 5Y $13.60 -93.17% +131.82% +224.99 2 Comments

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for INFI.